secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001104659-22-030025
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure reports FY 2021 net loss of $69.4M; cash $219.6M, expects funding into Q1 2024
--------------------------------------------------------------------------------

- Net loss $69.4M in 2021 vs $36.6M in 2020; no revenue recognized (Eli Lilly agreement ended).
- Cash, equivalents, marketable securities $219.6M at Dec 31, 2021, down $63.8M; expected to fund ops into Q1 2024.
- R&D expenses $50.2M in 2021 vs $46.6M; G&A $20.6M vs $17.0M primarily from headcount increases.
- Multiple 2022 data readouts planned: NC318 Phase 2 update Q4, NC410 update H2, NC762 initial Phase 1 data H2, NC525 IND filing Q4.
- COVID-19 pandemic delayed clinical trial enrollment, causing some milestones to be pushed back.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465922030025/0001104659-22-030025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465922030025/tm228329d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-030025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer